BC Week In Review | Nov 2, 2018
Clinical News

Grifols' AMBAR approach slows disease progression in moderate Alzheimer’s

Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) reported Phase IIb/III data on its AMBAR approach to treat Alzheimer’s disease demonstrating evidence of mechanism and improvements in clinical outcomes. AMBAR, which stands for Alzheimer Management by Albumin Replacement, was...
BC Extra | Oct 29, 2018
Clinical News

Grifols' AMBAR approach slows disease progression in moderate Alzheimer’s

Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) reported Phase IIb/III data on its AMBAR approach to treat Alzheimer’s disease demonstrating evidence of mechanism and improvements in clinical outcomes. AMBAR, which stands for Alzheimer Management by Albumin Replacement, was...
BioCentury | Nov 8, 1999
Tools & Techniques

Approved protein & antibody therapeutics

Approved protein & antibody therapeutics Company Product Indication Year first approved Alpha Therapeutic Albutein albumin Hypovolemic shock, hemodialysis and cardiopulmonary bypass 1986 Alphanate Factor VIII AlphaNine Factor IX Venoglobulin-S IgG Hemophilia A Hemophilia B Immunodeficiencies...
Items per page:
1 - 3 of 3